● Recruiting

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Condition: Epithelial Ovarian Cancer · Primary Peritoneal Carcinoma · Fallopian Tube Cancer · Sponsor: Regeneron Pharmaceuticals

PhasePhase 1

Planned participants90

Who can joinFemale, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. This study has two (2) major parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion. The aim of the dose escalation part will be to test the safety of 27T51 in a small number of participants to find the highest dose given to humans without unacceptable side effects. The aim of the dose expansion part will be to test 27T51 at the established dose level(s) from the dose escalation part and may include other medications given in combination with 27T51. Information collected from this study will help researchers understand more fully whether this immune cell therapy, also known as CAR T cell therapy, can be safely used to treat solid tumors such as ovarian cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com

Always discuss trial participation with your own doctor first.

Locations (5)

Massachusetts General Hospital	Boston, Massachusetts, United States	Recruiting
John Theurer Cancer Center Hackensack University Medical Center	Hackensack, New Jersey, United States	Recruiting
Roswell Park Cancer Institute	Buffalo, New York, United States	Recruiting
UPMC Hillman Cancer Center	Pittsburgh, Pennsylvania, United States	Recruiting
LDS Hospital	Salt Lake City, Utah, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06469281